NeuroMab™ Anti-EPHA2 BBB Shuttle Antibody,Clone NR2709P

Figure 1 Eph099B-208.261 can compete with EA2 for EphA2 binding in a competitive ELISA assay.

Figure 2 Antibody to EphA2 inhibits the growth of malignant tumor cells in soft agar.

single dose of 5 µg/ml of Eph099B-208.261 (black bars), EA2 (white bars) purified EphA2 antibody, or negative control antibody 1A7 (gray bars) was incubated with malignant MDA-MB-231 tumor cells to achieve the indicated levels in soft agar. time at 37°C. Results are reported as colonies per high power field (HPF).

Figure 3 EphA2 antibodies EA2, Eph099B-208.261 and Eph099B-233.152 inhibit tumor cell growth in vivo.

MDA-MB-231 breast cancer cells were implanted (A) orthotopically or (B) subcutaneously into athymic mice. (C) A549 lung cancer cells were implanted subcutaneously in athymic mice. After tumor growth to an average volume of 100 mm3, mice were administered 6 mg/kg of the indicated antibody or negative control (PBS or 1A7 antibody) intraperitoneally twice weekly for 3 weeks. Tumor growth was assessed and expressed as the ratio of tumor volume divided by initial tumor volume (100 mm3).

Figure 4 EphA2 antibodies EA2, Eph099B-208.261 and Eph099B-233.152 inhibit tumor cell growth in vivo.

MDA-MB-231 breast cancer cells were implanted subcutaneously in athymic mice. After tumor growth to an average volume of 100mm3, mice were dosed intraperitoneally with 6 mg/kg of the indicated antibody or negative control twice a week for 3 weeks. Total tumor volume was determined after sacrifice. The negative control is black, EA2 is white, Eph099B-208.261 is dark gray, and Eph099B-233.152 is light gray.

Figure 5 Kinetic analysis of EphA2 monoclonal antibodies.

The BIACORE™ (surface plasmon resonance-based) assay was used to determine the kinetics of binding of EphA2 mAb to immobilized EphA2-Fc. Eph099B-208.261 is represented by a solid line, Eph099B-233.152 is represented by a dotted line, EA2 is represented by a dotted line, and the negative control is represented by squares.